Vera Therapeutics (VERA) Stock Dropped, So What Is Behind The Move?

Vera Therapeutics (VERA) is back in focus after the FDA approved its IgA nephropathy treatment atacicept, now branded as Trutakna, following Phase III data showing meaningful proteinuria reductions.

The FDA approval has arrived after a tough stretch for Vera Therapeutics’ stock. The 30 day share price return is down 18.65% and the year to date share price return is down 42.66%, even though the 3 year total shareholder return is up 183.33%. Momentum has recently been fading rather than building.

Spot potential follow up opportunities around Vera Therapeutics' news by scanning a curated list of 33 healthcare AI stocks that are also working on data driven advances in diagnostics and treatment.

So, after a sharp slide in Vera Therapeutics despite Trutakna clearing the FDA, does the current valuation still compensate you for the clinical, launch, and financing risks from here?

Most Popular Narrative: 64% Undervalued

At a last close of $27.88 versus a narrative fair value of $77.50, Vera Therapeutics is framed as heavily discounted despite the recent drawdown and the fresh FDA approval for Trutakna.

The current setup implies that Vera Therapeutics’ share price reflects skepticism that premium TRUTAKNA pricing, early patient start form momentum and a long intellectual property runway into the 2040s will translate into a larger and more durable IgAN and autoimmune kidney disease franchise.

See why 1 investors see Vera Therapeutics as 64% undervalued.

Result: Fair Value of $77.50 (UNDERVALUED)

Still, the Vera Therapeutics story can change quickly if TRUTAKNA uptake lags current analyst revenue forecasts or if investors reassess paying a 78.8x future P/E.

Find out about the key risks to this Vera Therapeutics narrative.

Another View on Vera Therapeutics’ Valuation

Those fair value estimates lean on long term earnings forecasts and a high future P/E. On a simpler yardstick like P/B, Vera Therapeutics looks expensive at 4.9x versus 1.9x for the US biotech group and 3.6x for peers, which points to less margin for error if expectations change.

That gap matters, because a higher P/B multiple means you are paying more today for each dollar of net assets, so any stumble in Trutakna uptake or future financing would be felt more quickly in the share price.

See what the numbers say about this price in our valuation breakdown, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Sentiment around Vera Therapeutics is mixed and the data cuts both ways, so this is a moment to move fast and test the numbers yourself before the narrative shifts. To weigh both sides properly, start with the headline positives and negatives in our breakdown of 2 key rewards and 1 important warning sign

Looking For More Investment Ideas Beyond Vera Therapeutics?

If Vera Therapeutics has sharpened your thinking, do not stop here. Broaden your watchlist now and give yourself more than one way to win.

• Target resilient upside by reviewing 33 high quality undervalued stocks with solid fundamentals that could offer more attractive entry points.
• Prioritise sleep-at-night stability through a 32 resilient stocks with low risk scores that focuses on businesses with sturdier risk profiles.
• Hunt for tomorrow’s leaders early by scanning a 20 high quality undiscovered gems that highlights quality companies still flying under most investors’ radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com